---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-070151"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2023-06-12T23:59:59+00:00"
generated_at: "2026-06-14T02:39:35.366478+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics treats first lymphoma patient in Phase 1 APOLLO trial of MT-601

## Summary
- First patient dosed at 200 million cells; no treatment-related adverse events after 18 days.
- Trial enrolls up to 30 patients across 8 U.S. sites for lymphoma patients relapsed after or ineligible for anti-CD19 CAR T therapy.
- MT-601 targets six tumor antigens; prior TACTAL study showed durable responses with a five-antigen product.
- Nonclinical data from May 2023 showed MT-601 inhibited lymphoma cells regardless of CD19 expression and overcame CAR T resistance.

## SEC filing metadata
- accession: 0001104659-23-070151
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2023-06-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465923070151/0001104659-23-070151-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465923070151/tm2317378d3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-070151
- JSON: https://secwatch.observer/filing/0001104659-23-070151.json
- Plain text: https://secwatch.observer/filing/0001104659-23-070151.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.